Literature DB >> 20534475

A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses.

Kazu Matsumoto1, Fumitoshi Irie, Susan Mackem, Yu Yamaguchi.   

Abstract

Multiple hereditary exostoses (MHE) is one of the most common skeletal dysplasias, exhibiting the formation of multiple cartilage-capped bony protrusions (osteochondroma) and characteristic bone deformities. Individuals with MHE carry heterozygous loss-of-function mutations in Ext1 or Ext2, genes which together encode an enzyme essential for heparan sulfate synthesis. Despite the identification of causative genes, the pathogenesis of MHE remains unclear, especially with regard to whether osteochondroma results from loss of heterozygosity of the Ext genes. Hampering elucidation of the pathogenic mechanism of MHE, both Ext1(+/-) and Ext2(+/-) heterozygous mutant mice, which mimic the genetic status of human MHE, are highly resistant to osteochondroma formation, especially in long bones. To address these issues, we created a mouse model in which Ext1 is stochastically inactivated in a chondrocyte-specific manner. We show that these mice develop multiple osteochondromas and characteristic bone deformities in a pattern and a frequency that are almost identical to those of human MHE, suggesting a role for Ext1 LOH in MHE. Surprisingly, however, genotyping and fate mapping analyses reveal that chondrocytes constituting osteochondromas are mixtures of mutant and wild-type cells. Moreover, osteochondromas do not possess many typical neoplastic properties. Together, our results suggest that inactivation of Ext1 in a small fraction of chondrocytes is sufficient for the development of osteochondromas and other skeletal defects associated with MHE. Because the observed osteochondromas in our mouse model do not arise from clonal growth of chondrocytes, they cannot be considered true neoplasms.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534475      PMCID: PMC2890731          DOI: 10.1073/pnas.0914642107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Kinetics of tamoxifen-regulated Cre activity in mice using a cartilage-specific CreER(T) to assay temporal activity windows along the proximodistal limb skeleton.

Authors:  Eiichiro Nakamura; Minh-Thanh Nguyen; Susan Mackem
Journal:  Dev Dyn       Date:  2006-09       Impact factor: 3.780

2.  Decreased EXT expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas.

Authors:  L Hameetman; G David; A Yavas; S J White; A H M Taminiau; A-M Cleton-Jansen; P C W Hogendoorn; J V M G Bovée
Journal:  J Pathol       Date:  2007-03       Impact factor: 7.996

3.  EXT1 regulates chondrocyte proliferation and differentiation during endochondral bone development.

Authors:  Matthew J Hilton; Laura Gutiérrez; Daniel A Martinez; Dan E Wells
Journal:  Bone       Date:  2005-03       Impact factor: 4.398

4.  EXT-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas.

Authors:  J V Bovée; A M Cleton-Jansen; W Wuyts; G Caethoven; A H Taminiau; E Bakker; W Van Hul; C J Cornelisse; P C Hogendoorn
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

Review 5.  Manifestations of hereditary multiple exostoses.

Authors:  Jonathan R Stieber; John P Dormans
Journal:  J Am Acad Orthop Surg       Date:  2005 Mar-Apr       Impact factor: 3.020

6.  Mice deficient in Ext2 lack heparan sulfate and develop exostoses.

Authors:  Dominique Stickens; Beverly M Zak; Nathalie Rougier; Jeffrey D Esko; Zena Werb
Journal:  Development       Date:  2005-10-19       Impact factor: 6.868

7.  The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate.

Authors:  C McCormick; Y Leduc; D Martindale; K Mattison; L E Esford; A P Dyer; F Tufaro
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

8.  Heparan sulfate regulates ephrin-A3/EphA receptor signaling.

Authors:  Fumitoshi Irie; Misako Okuno; Kazu Matsumoto; Elena B Pasquale; Yu Yamaguchi
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-20       Impact factor: 11.205

9.  The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate.

Authors:  T Lind; F Tufaro; C McCormick; U Lindahl; K Lidholt
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

10.  The role of EXT1 in nonhereditary osteochondroma: identification of homozygous deletions.

Authors:  Liesbeth Hameetman; Karoly Szuhai; Ayse Yavas; Jeroen Knijnenburg; Mark van Duin; Herman van Dekken; Antonie H M Taminiau; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Pancras C W Hogendoorn
Journal:  J Natl Cancer Inst       Date:  2007-03-07       Impact factor: 13.506

View more
  39 in total

1.  Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice.

Authors:  Federica Sgariglia; Maria Elena Candela; Julianne Huegel; Olena Jacenko; Eiki Koyama; Yu Yamaguchi; Maurizio Pacifici; Motomi Enomoto-Iwamoto
Journal:  Bone       Date:  2013-08-17       Impact factor: 4.398

2.  Heparan sulfate antagonism alters bone morphogenetic protein signaling and receptor dynamics, suggesting a mechanism in hereditary multiple exostoses.

Authors:  Christina Mundy; Evan Yang; Hajime Takano; Paul C Billings; Maurizio Pacifici
Journal:  J Biol Chem       Date:  2018-04-05       Impact factor: 5.157

3.  Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency.

Authors:  Carlos E de Andrea; Ju-Fen Zhu; Huifeng Jin; Judith V M G Bovée; Kevin B Jones
Journal:  J Pathol       Date:  2015-03-03       Impact factor: 7.996

Review 4.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

5.  Compound heterozygous loss of Ext1 and Ext2 is sufficient for formation of multiple exostoses in mouse ribs and long bones.

Authors:  Beverly M Zak; Manuela Schuksz; Eiki Koyama; Christina Mundy; Dan E Wells; Yu Yamaguchi; Maurizio Pacifici; Jeffrey D Esko
Journal:  Bone       Date:  2011-02-15       Impact factor: 4.398

Review 6.  Glycobiology and the growth plate: current concepts in multiple hereditary exostoses.

Authors:  Kevin B Jones
Journal:  J Pediatr Orthop       Date:  2011 Jul-Aug       Impact factor: 2.324

Review 7.  The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses.

Authors:  Maurizio Pacifici
Journal:  Matrix Biol       Date:  2017-12-24       Impact factor: 11.583

8.  Palovarotene Inhibits Osteochondroma Formation in a Mouse Model of Multiple Hereditary Exostoses.

Authors:  Toshihiro Inubushi; Isabelle Lemire; Fumitoshi Irie; Yu Yamaguchi
Journal:  J Bone Miner Res       Date:  2017-11-30       Impact factor: 6.741

9.  Perichondrium phenotype and border function are regulated by Ext1 and heparan sulfate in developing long bones: a mechanism likely deranged in Hereditary Multiple Exostoses.

Authors:  Julianne Huegel; Christina Mundy; Federica Sgariglia; Patrik Nygren; Paul C Billings; Yu Yamaguchi; Eiki Koyama; Maurizio Pacifici
Journal:  Dev Biol       Date:  2013-03-01       Impact factor: 3.582

Review 10.  Cell biology of osteochondromas: bone morphogenic protein signalling and heparan sulphates.

Authors:  Araceli Cuellar; A Hari Reddi
Journal:  Int Orthop       Date:  2013-06-15       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.